TRex Bio, Inc. (NASDAQ:TRXB) Stock Short Interest Report for October

TRex Bio, Inc. (NASDAQ:TRXB) was the recipient of a large growth in short interest during the month of October. As of October 15th, there was short interest totaling 195,608 shares. Based on an average daily volume of 183,613 shares, the days-to-cover ratio is currently 1.1 days.

TRex Bio Stock Performance

NASDAQ:TRXB opened at $13.74 on Friday. TRex Bio has a twelve month low of $13.10 and a twelve month high of $16.56.

Insider Transactions at TRex Bio

In other news, major shareholder Alexandria Venture Investments purchased 178,571 shares of the business’s stock in a transaction on Tuesday, October 13th. The shares were acquired at an average cost of $14.00 per share, with a total value of $2,499,994.00. Following the completion of the acquisition, the insider owned 1,346,501 shares of the company’s stock, valued at $18,851,014. This trade represents a 15.29% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

TRex Bio Company Profile

We are a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio was built on a pivotal scientific insight: that regulatory T cells (“Tregs”) in human tissue are not merely passive suppressors of inflammation, but active orchestrators of tissue immune homeostasis and repair.